U.S. markets open in 4 hours

Intra-Cellular Therapies, Inc. (ITCI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
35.03+1.60 (+4.79%)
At close: 4:00PM EDT

Intra-Cellular Therapies, Inc.

430 East 29th Street
Suite 900
New York, NY 10016
United States
646 440 9333

Full Time Employees383

Key Executives

NameTitlePayExercisedYear Born
Dr. Sharon MatesCo-Founder, Chairman, CEO & Pres1.52M189.42k1953
Mr. Lawrence J. Hineline CPA, CPASr. VP of Fin., CFO, Treasurer & Assistant Sec.693.55k336.9k1956
Mr. Michael I. Halstead J.D.Exec. VP, Gen. Counsel & Sec.837.47kN/A1973
Mr. Mark NeumannEVP & Chief Commercial Officer914.35kN/A1963
Dr. Robert E. DavisSr. VP & Chief Scientific OfficerN/AN/A1951
Mr. Juan Fernando SanchezVP of Corp. Communications & Investor RelationsN/AN/A1971
Ms. Karen Patruno Sheehy Esq.Sr. VP & Chief Compliance OfficerN/AN/A1962
Dr. Suresh K. Durgam M.D.Sr. VP & Chief Medical OfficerN/AN/A1969
Dr. Michael OlchaskeySr. VP & Head of Regulatory AffairsN/AN/AN/A
Mr. John A. BardiSr. VP of Market Access, Policy & Gov. AffairsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Corporate Governance

Intra-Cellular Therapies, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 5. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.